Boehringer Ingelheim and King’s College London Join Forces to Progress New Therapeutic Concepts in Major Depressive Disorder and Schizophrenia

Boehringer Ingelheim and the Institute of Psychiatry, Psychology & Neuroscience at King’s College London announced a new collaboration focused on understanding the malfunctions in brain circuits that drive impaired cognition in people with major depressive disorder and schizophrenia.